CClinicalTrials.gg
CompletedNCT06167200SCC_DOCUpdated Feb 6, 2025

Validation of a Clinical Complications Scale (CCS) in Patients with Disorders of Consciousness

An observational study in Disorders of Consciousness, sponsored by Fondazione Don Carlo Gnocchi Onlus. Completed at 6 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-06.

Sponsored by Fondazione Don Carlo Gnocchi Onlus · Observational

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
42
Ages
18 Years and older
Sex
All
01

Study summary

The clinical condition of severe cognitive-motor impairment of Disorders of Consciousness (DoC; e.g., Vegetative State - VS, and Minimal Consciousness State - MCS), is characterized by a high risk of developing clinical complications. In this study, the investigators propose a new Clinical Complications Scale (CCS) developed to assess the impact of clinical complications on the long-term evolution of a cohort of patients with DoC.

This is a multi-site prospective observational study conducted in patients with Severe Acquired Brain Injury and DoC admitted to six centers of Fondazione Don Gnocchi (Italy), with clinical data collection not deviating from routine practice (except for CCS administration). The study is non-commercial and will have a maximum total duration of 24 months. It is planned to assess inter-rater agreement and concurrent validity with a similar instrument (CoCoS scale).

Read the detailed description

Validation of a scale for the assessment of clinical complications (Clinical Complications Scale, CCS) on a sample of DoC patients with:

  • assessment of inter-rater agreement;
  • assessment of concurrent validity with a similar instrument (CoCoS).

This study will be implemented throutgh three phases:

(i) Identification of a group of evaluators at participating centers (n=3 per center; total n=18) and training them to administer the CCS and CoCos scales by group videoconference; (ii) Recruitment of a sample of DoC patients (n=7 per center; total n=42) who will each undergo assessment with CCS (administered twice by two independent assessors, A and B) and with CoCoS (administered by a third independent assessor, C); (iii) Evaluation of the degree of agreement between observers in administering the CCS scale (agreement between evaluators A and B) and evaluation of concurrent validity between CCS and CoCoS scale (agreement between evaluators A/B and C).

The study involves the collection of the following clinical data for each patient on admission and during the following 15 days:

  • Demographic data respecting patient anonymity (patient's numeric identification code, age, sex, ethnicity, education);
  • Anamnestic data (date and etiology of acute event);
  • Clinical data including blood chemistry tests, clinical complications and related therapies administered as per normal clinical reports in use at enrolling units, and referring to the 15-day period following the date of enrollment. Each patient also will be evaluated with CRS-R scale 3-5 times within one week after enrollment for confirmation of the diagnosis of DoC. Assessments with CCS and CoCoS clinical scales completed on clinical reports referring to medical complications that occurred within 15 days of enrollment.

The CCS provides a record of clinical complications in 11 categories corresponding to systems of the body (metabolic abnormalities, disorders-cardiovascular, skin and musculoskeletal problems, gastrointestinal disorders, genito-urinary disorders, respiratory disorders) or categories of clinical problems frequently encountered in the population of patients with DoC (neurosurgical complications, epilepsy and myoclonus, paraosteortropathy, neurovegetative crisis, sepsis; Estraneo et al., 2018). For each category, the severity of complications is graded from 0 (absent complication) to 3 (severe complication) based on the intensity of the therapeutic intervention required, interference with the clinic, and/or frequency and duration of morbid events (an exception is the "sepsis" category for which only presence/absence is recorded). In the case of multiple clinical complications occurring within the same category, the most severe will be considered for the severity score. In this way, a cumulative scale score with range 0-31 can be derived.

Descriptive data from the sample at study entry will be expressed in terms of mean and standard deviation for quantitative variables and as frequencies for nominal variables. For the assessment of inter-rater agreement in the administration of the CCS, Fleiss' weighted K-index will be calculated on the individual subscale scores and the total score of the scale administered to each patient by two different operators. For concurrent validity testing between the CCS and CoCoS scales, Fleiss' weighted K-index will be calculated between the scores at the subscales in common between the two instruments, while Spearman's correlation coefficient for ranks will be calculated on the total scores obtained by patients on the two scales.

02

Conditions studied

  • Disorders of Consciousness

Keywords

  • Disorders of Consciousness
  • clinical complications
03

In context

Consciousness Disorders

236 studies on the registry are indexed under Consciousness Disorders; 101 are open to participants now.

This study's enrollment of 42 is below the median of 79 across 86 observational studies indexed under Consciousness Disorders.

Browse Consciousness Disorders studies →

Lead sponsor

Fondazione Don Carlo Gnocchi Onlus is the lead sponsor of 146 studies on the registry; 37 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients in VS or MCS due to severe acquired brain injury with different etiology (traumatic, anoxic, vascular) consecutively admitted at participating neurorehabilitation units. The total sample will be composed of 42 patients (n=7 pts per participating unit).

Inclusion criteria

  • Clinical diagnosis of VS or MCS, in accordance with international standard diagnostic criteria (Giacino et al., 2002) and confirmed by Coma Recovery Scale-Revised (CRS-R; Giacino et al., 2004) assessment repeated 3-5 times within a week (Wannez et al., 2017);
  • Time post-injury ≥28 days;
  • age ≥18 years;
  • Traumatic, vascular, anoxic, or mixed etiology.

Exclusion criteria

Exclusion Criteria:

  • Absence of the informed consent by the patient's legal representative.
05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
42 participants (actual)
Target follow-up
15 Days
Patient registry
Yes

Groups and cohorts

  • Patients with DoC consecutively admitted to participating units and met the inclusion criteria

    Patients in VS or MCS due to severe acquired brain injury with different etiology (traumatic, anoxic, vascular) consecutively admitted at participating neurorehabilitation units. The total sample will be composed of 42 patients (n=7 pts per participating unit).

    Other: No intervention, study is observational

Interventions

  • OtherNo intervention, study is observational

    No intervention, study is observational

06

What researchers measure

Primary outcomes

  1. inter-rater reliability

    agreement in scores between different examiners

    Time frame: 15 days from enrolment

  2. concurrent validity

    correlation between scores on the CCS and the CoCoS

    Time frame: 15 days from enrolment

07

Study locations

6 sites
  • Polo Specialistico Riabilitativo Fondazione Don Carlo Gnocchi ONLUS
    Sant'Angelo Dei Lombardi, Avellino 83054, Italy
  • IRCCS Fondazione Don Carlo Gnocchi Firenze
    Firenze, Italy
  • Polo Riabilitativo del Levante Ligure Fondazione Don Gnocchi
    La Spezia, Italy
  • IRCCS S. Maria Nascente Fondazione Don Gnocchi
    Milano, Italy
  • Istituto Palazzolo Fondazione Don Gnocchi
    Milano, Italy
  • Centro Spalenza Fondazione Don Gnocchi
    Rovato, Italy
08

References and documents

Publications

  • Giacino JT, Ashwal S, Childs N, Cranford R, Jennett B, Katz DI, Kelly JP, Rosenberg JH, Whyte J, Zafonte RD, Zasler ND. The minimally conscious state: definition and diagnostic criteria. Neurology. 2002 Feb 12;58(3):349-53. doi: 10.1212/wnl.58.3.349. PubMed 11839831 ↗
  • Wannez S, Heine L, Thonnard M, Gosseries O, Laureys S; Coma Science Group collaborators. The repetition of behavioral assessments in diagnosis of disorders of consciousness. Ann Neurol. 2017 Jun;81(6):883-889. doi: 10.1002/ana.24962. PubMed 28543735 ↗
  • Pistoia F, Carolei A, Bodien YG, Greenfield S, Kaplan S, Sacco S, Pistarini C, Casalena A, De Tanti A, Cazzulani B, Bellaviti G, Sara M, Giacino J. The Comorbidities Coma Scale (CoCoS): Psychometric Properties and Clinical Usefulness in Patients With Disorders of Consciousness. Front Neurol. 2019 Oct 17;10:1042. doi: 10.3389/fneur.2019.01042. eCollection 2019. PubMed 31681139 ↗
  • Estraneo A, Loreto V, Masotta O, Pascarella A, Trojano L. Do Medical Complications Impact Long-Term Outcomes in Prolonged Disorders of Consciousness? Arch Phys Med Rehabil. 2018 Dec;99(12):2523-2531.e3. doi: 10.1016/j.apmr.2018.04.024. Epub 2018 May 26. PubMed 29807003 ↗
  • Giacino JT, Kalmar K, Whyte J. The JFK Coma Recovery Scale-Revised: measurement characteristics and diagnostic utility. Arch Phys Med Rehabil. 2004 Dec;85(12):2020-9. doi: 10.1016/j.apmr.2004.02.033. PubMed 15605342 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06167200
Lead sponsor
Fondazione Don Carlo Gnocchi Onlus
Responsible party
Anna Estraneo (Neurologist, Senior Researcher, Fondazione Don Carlo Gnocchi Onlus) — Principal investigator
First posted
Dec 12, 2023
Start date
May 15, 2024
Primary completion
Nov 30, 2024
Completion
Dec 30, 2024
Last update
Feb 6, 2025

Study contacts

Anna Estraneo, MD
principal investigator · Fondazione Don Carlo Gnocchi Onlus

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion